Dr. Bernstein is featured in a New York Times article — “New Stratagems in the Quest for Hair” — about the latest advances in hair restoration. The article mentions Dr. Bernstein’s pioneering research on hair cloning, including his studies on hair multiplication using the breakthrough biotechnology of ACell’s MatriStem^® extracellular matrix.

Research published in the January 2011 issue of the Journal of Clinical Investigation (Vol. 121, issue 1) reveals another breakthrough in the medical community’s understanding of the causes of — and possible cure for — androgenetic alopecia, or common male pattern baldness. The new research shows that the presence of a certain type of cell, called a progenitor cell, is significantly reduced in men with common baldness compared to men who are not bald. Read on for more details on this breakthrough.

Latisse, the brand name for the drug bimatoprost, is commonly used to promote eyelash growth in women who want their eyelashes to be longer, thicker, and darker, typically for cosmetic reasons.

In a publication on ClinicalTrials.gov, Allergan, the pharmaceutical company that produces Latisse, has announced a new study on the safety and efficacy of a new formulation of bimatoprost for use as a topical hair loss treatment for general baldness.